India Radiotherapy Devices Market Report and Forecast 2026-2034

Study Period

2021-2034

Market (2025)

USD 165.72 Million

Market (2034)

USD 393.65 Million

CAGR

10.09%

Major Markets Players

Siemens Healthcare Diagnostics Ltd., Elekta Medical Systems India Pvt. Ltd, Koninklijke Philips N.V., Accuray Medical Equipment India Pvt. Ltd., Hitachi High-Tech India Pvt. Ltd. and Others

*Note: Partial List Randomly Ordered

India Radiotherapy Devices Market Statistics and Insights

India Radiotherapy Devices Market Insights & Analysis

The India Radiotherapy Devices Market is anticipated to register a 10.09% CAGR during 2026–2034. The market size was valued at USD 165.72 million in 2025 and is projected to reach USD 393.65 million by 2034. India's oncology infrastructure has undergone significant modernization, driven by increasing cancer burden and rising government investments in healthcare. According to the Indian Council of Medical Research (ICMR), India recorded over 1.46 million new cancer cases in 2022, with the number forecast to cross 1.57 million by 2025.

This escalating disease prevalence is creating sustained procurement demand for advanced radiotherapy systems across tertiary hospitals, cancer specialty centers, and regional cancer institutes. The National Cancer Grid (NCG), comprising over 270 cancer centers, has prioritized the standardization and upgrade of radiation therapy protocols. Additionally, the Pradhan Mantri Jan Arogya Yojana (PM-JAY) scheme has extended insurance coverage for cancer treatment to nearly 107 million households, broadening patient access and accelerating device adoption across public and private healthcare sectors.

India Radiotherapy Devices Market Dynamics

Key Market Driver: Rising Cancer Burden Fuels Procurement

India's rapidly growing cancer incidence is the primary engine propelling demand for radiotherapy devices. Cervical cancer, breast cancer, and oral cancers collectively account for over 34% of new cases annually in India, requiring high-throughput radiation delivery systems. Government-backed programs such as the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases & Stroke (NPCDCS) have channeled over INR 2,100 crore into oncology infrastructure between 2021 and 2024. The growing tier-2 and tier-3 city hospital network, with over 180 new oncology units commissioned since 2022, is catalyzing device placements beyond metropolitan hubs, deepening market penetration and sustaining double-digit growth across the radiotherapy equipment segment.

Major Industry Challenge: Shortage of Trained Radiation Oncologists

A significant structural constraint limiting market expansion is the critical shortage of qualified radiation oncologists and medical physicists in India. With an estimated requirement of over 5,000 radiation oncologists nationally, the current supply stands at approximately 1,200–1,500 active practitioners, according to data from the Association of Radiation Oncologists of India (AROI).

This workforce gap results in underutilization of installed radiotherapy equipment, particularly in non-metro hospitals that struggle to attract and retain specialized personnel. Furthermore, regulatory licensing timelines for radiation-emitting equipment under the Atomic Energy Regulatory Board (AERB) can extend to 12–18 months, delaying device commissioning and revenue realization for both manufacturers and healthcare providers.

Emerging Trend Shaping Outlook: Adaptive Radiotherapy and Proton Therapy Uptake

India is witnessing accelerating adoption of advanced modalities such as stereotactic body radiotherapy (SBRT), intensity-modulated radiation therapy (IMRT), and early-stage proton therapy. Apollo Hospitals commissioned India's first proton therapy center in Chennai in 2023, and Tata Memorial Centre in Mumbai is in advanced stages of deploying a second proton facility by 2026.

These high-precision systems reduce collateral tissue damage, improving patient outcomes for pediatric and central nervous system cancers. Adaptive radiotherapy platforms that leverage real-time imaging to adjust dose delivery are gaining traction among leading private cancer hospitals, setting a new benchmark for clinical efficacy and propelling premium device sales throughout the forecast period.

India Radiotherapy Devices Market Segment-wise Analysis

India's radiotherapy devices landscape is shaped by technology diversification and a widening oncology application base. The interplay between device type innovation and cancer-type-specific clinical protocols defines procurement patterns across hospitals, standalone cancer centers, and government-funded regional cancer institutes.

By Type

• External Beam Radiation Therapy Device
• Internal Beam Radiation Therapy Device
• Others

External Beam Radiation Therapy (EBRT) devices account for approximately 62% of the India radiotherapy devices market by revenue. This dominance is attributable to the widespread clinical acceptance of linear accelerators (LINACs), which are now the standard of care in most oncology departments. Hospitals such as AIIMS, Tata Memorial, and HCG have invested heavily in EBRT platforms, particularly advanced LINACs with image-guided capabilities.

The segment benefits from ongoing replacement cycles as older Cobalt-60 units are phased out in compliance with AERB directives. Internal Beam Radiation Therapy (brachytherapy) devices hold approximately 28% market share and are particularly critical for cervical and prostate cancer treatment, where close-proximity radioactive source delivery achieves superior dose conformity. The Others segment, comprising proton therapy and neutron therapy units, currently holds around 10% share but is expected to register the fastest growth rate through 2034, driven by capacity expansion at premier cancer institutes.

By Application

• Breast Cancer
• Cervical Cancer
• Colon and Rectum Cancers
• Stomach Cancer
• Lung Cancer
• Prostate Cancer
• Skin Cancer
• Liver Cancer
• Other

Breast cancer holds the leading application share at approximately 22%, reflecting India's status as one of the highest-burden countries for this disease, with over 178,000 new cases registered in 2022 per ICMR data. Adjuvant radiotherapy post-surgery is a standard protocol, sustaining consistent device utilization across oncology centers. Cervical cancer constitutes around 18% of application revenue, driven by high incidence in rural and semi-urban populations.

Lung cancer is the third-largest application segment at approximately 14%, propelled by increasing tobacco use and air quality deterioration in major Indian cities. Prostate cancer is emerging as a fast-growing sub-segment, benefiting from rising PSA screening awareness and the adoption of stereotactic ablative radiotherapy (SABR). Liver cancer treatment using Selective Internal Radiation Therapy (SIRT) is gaining clinical acceptance in hepatology-oncology departments of multi-specialty hospitals.

Regional Projection of India Radiotherapy Devices Market

India's radiotherapy devices market exhibits pronounced regional concentration, influenced by oncology infrastructure density and government investment distribution.

• North India
• South India
• West India
• East India

South India leads the India Radiotherapy Devices Market with an estimated 31% market share, driven by the presence of high-volume cancer centers such as HCG Oncology, Apollo Hospitals' oncology network, and Kidwai Memorial Institute of Oncology in Bengaluru. Tamil Nadu and Karnataka host a disproportionately high concentration of private oncology hospitals with advanced EBRT and brachytherapy suites. North India holds the second-largest share, anchored by AIIMS New Delhi and leading private institutions in Delhi-NCR. West India is the third-largest region, with Maharashtra contributing significantly through Tata Memorial Centre's Mumbai campus.

India Radiotherapy Devices Market: Recent Development (2025)

• Elekta Medical Systems India signed a multi-unit LINAC supply agreement with HCG Oncology network in Q1 2025.
• Varian Medical Systems reported a 14% revenue margin uplift in India following three new EDGE radiosurgery system installations.
• Siemens Healthcare Diagnostics expanded its Gurgaon service hub, supporting 40 additional radiotherapy devices across North India.
• Accuray Medical Equipment India Pvt. Ltd. posted an 11.2% gross margin increase after deploying CyberKnife systems in Mumbai hospitals.

India Radiotherapy Devices Market Future Outlook (2034)

The India Radiotherapy Devices Market is positioned for sustained high-growth trajectory, forecast to reach USD 393.65 million by 2034 at a 10.09% CAGR. The outlook is underpinned by converging forces: expanding National Cancer Grid infrastructure, rising medical tourism inflows into Indian cancer centers, and progressive AERB regulatory modernization.

Technology advancement in AI-assisted treatment planning, including automated contouring and adaptive dose optimization, will reduce workflow bottlenecks and improve radiation precision. The entry of proton therapy and MR-Linac hybrid systems into mid-tier private hospital networks will unlock a premium device segment currently untapped. Public-private partnership models, particularly under the Ayushman Bharat Digital Mission, will further democratize access to radiotherapy services, driving long-term volume expansion across all device categories through 2034

Why Choose This Report?

• Provides a comprehensive overview of the overall market analysis, encompassing key trends, consumer behavior analysis, and risk assessment to support strategic decision-making.
• Provides accurate, up-to-date insights into market size, segmentation, and emerging opportunities, helping to minimize risk & capitalizing on growth.
• Gives deep understanding of target audience preferences, investment habits, and communication channels for enhanced product development & marketing effectiveness.
• Delivers competitive analysis & benchmarking, uncovering the strengths & weaknesses of market competitors to guide strategies.
• Consolidate comprehensive market intelligence, reducing reasoning & streamlining research efforts.
• Facilitates customized market segmentation & risk mitigation strategies, fine-tuned to the business objectives.
• Aids in identifying both market challenges & untapped opportunities within the industry to drive long-term business growth.
• Provides valuable information based on actual customer data & search trends.